Atsign Advances Private Website Security with the Power of Invisibility

SAN JOSE, Calif., March 31, 2025 (GLOBE NEWSWIRE) — Atsign today announced that NoPorts(TM) fundamentally changes how private websites are secured. Unlike current systems where the web entry point is visible to anyone on the internet, NoPorts makes the entire website invisible until a person is cryptographically authenticated. This eliminates a significant attack vector, ensuring […]

iRhythm Unveils New Real-World Data at ACC.25 Demonstrating the Benefits of Zio(R) Long-Term Continuous Monitoring for Arrhythmia Detection

(NASDAQ:IRTC), SAN FRANCISCO, March 31, 2025 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced results from two large real-world retrospective analyses presented at the American College of Cardiology (ACC) 2025 Scientific Sessions in Chicago, IL. Drawing on data from more than 1.1 million patients who used iRhythm's Zio(R) long-term continuous monitoring (LTCM) ECG devices,

NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas

(NasdaqGM:NTHI), WESTLAKE VILLAGE, Calif., March 31, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NASDAQ Global Market: NTHI), a clinical-stage medical biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to perillyl alcohol (NEO100(TM)) for the treatment of pediatric-type diffuse high-grade gliomas, a serious and

PEAK3 and ASUS IoT Partner to Deliver Next-Generation Broadcast Technology to Edge Computing

Partnership brings broadcast-powered data delivery to edge devices, eliminating connectivity bottlenecks for smart city and industrial applications PEAK3 Spectrum and ASUS IoT announced today a strategic partnership that will integrate PEAK3's Industrial ATSC 3.0 M.2 Receiver technology into ASUS IoT's hardware platforms, creating new possibilities for smart cities and industrial automation. https://mma.prnewswire.com/media/2653474/ASUS_PEAK_PHOTO.jpg The collaboration combines

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Definitive Purchase Agreement with Dura Medical; Initial Acquisition for Planned International Network of Interventional Psychiatry Clinics

— Dura Medical, together with previously-announced acquisition of Neurospa TMS, will provide coverage throughout the West Coast of Florida — Delivers a full range of precision psychiatry services for severe depression and PTSD, including Ketamine Therapy and Transcranial Magnetic Stimulation (TMS), to veteran and civilian patients — Stephen Durand, founder of Dura, to serve as

Lindt Unveils GOLD BUNNY Hide and Seek: A Magical Easter Game for Canadian Families

Innovative game invites Canadians to search for hidden bunnies and hop out with a coupon This Easter,Lindt & Sprüngli is making easter moments magical for Canadian families and elevating their traditions with a playful twist on the beloved Easter egg hunt. Introducing GOLD BUNNY hide and seek, a magical Easter game that invites Canadians to

Contango Announces $24.0 Million in Cash Distribution from the Peak Gold JV and Completion of First Campaign of 2025

Contango ORE, Inc. (“Contango” or the “Company”) (NYSE American: CTGO) is pleased to announce that the Peak Gold JV has made cash distributions totaling $24 million (“M”) to Contango in the first quarter of 2025 (“Q1-2025”). These distributions consist of two payments: $9 M related to additional cash profits from 2024 production, paid on March

WELL Health Reports Record Patient Visits and Total Care Interactions in FY 2024

— WELL delivered more than 5.7 million patient visits in fiscal 2024 representing YoY growth of 32% driven mostly by organic growth of 30% — WELL Canada's patient services business led its overall growth with 3.125 million patient visits representing YoY growth of 35% growth and organic growth of 32% — WELL Canada's organic growth

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

(NASDAQ:APLM),(NASDAQ:APLMW), LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong Kong and Macau) for the treatment of non-small cell lung cancer (“NSCLC”) Apollomics to receive upfront payments of $10 million, and is eligible for pre-commercial milestones up to $50 million, and royalties on

Scroll to Top